| answer text |
<p>UK Research and Innovation (UKRI) funds research into epilepsy primarily through
the Medical Research Council and the Biotechnology and Biological Sciences Research
Council.</p><p>Funding for research projects that specifically refer to epilepsy in
the project title or abstract in each of the last five years are set out in the table
below. This does not include wider funding that contributes to epilepsy research.</p><p>
</p><table><tbody><tr><td><p><strong>Financial year 2014/2015</strong></p></td><td><p><strong>Financial
year 2015/2016</strong></p></td><td><p><strong>Financial year 2016/2017</strong></p></td><td><p><strong>Financial
year 2017/2018</strong></p></td><td><p><strong>Financial year 2019/2020</strong></p></td></tr><tr><td><p>£8m</p></td><td><p>£6.2m</p></td><td><p>£8.4m</p></td><td><p>£9.7m</p></td><td><p>£10.6m</p></td></tr></tbody></table><p>
</p><p>The DHSC-funded National Institute for Health Research (NIHR) facilitates and
enables life science research, from early translational research, through clinical
research, to applied health research. Life science companies can access NIHR resources
at any stage in their clinical development process and DHSC ensures all parts of the
NIHR are open to collaboration with industry.</p><p>The Government is committed to
making the UK a global hub for life sciences. This means building on our strengths
in basic science and medical research to ensure the UK remains at the forefront of
worldwide efforts to tackle the most pressing healthcare challenges, from cancer to
dementia.</p><p>As part of our commitment, the Government will raise total UK investment
in R&D to 2.4% of GDP by 2027. Life Sciences is critical to this – with the pharmaceutical
industry accounting for one fifth of the total industrial spend on R&D in the
UK<sup>1</sup>.</p><p>We will also continue to support our fantastic research infrastructure,
which bolsters the sector, stimulates economic growth and drives better outcomes for
patients.</p>
|
|
